Get the Stockscreener App
2.04
17.24%
0.30
Pre-market:
2.01
-0.03
-1.47%
Bioxcel Therapeutics Inc stock is traded at $2.04, with a volume of 2.33M.
It is up +17.24% in the last 24 hours and down -1.45% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$1.74
Open:
$1.81
24h Volume:
2.33M
Relative Volume:
3.22
Market Cap:
$44.61M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.3322
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
+27.50%
1M Performance:
-1.45%
6M Performance:
+7.37%
1Y Performance:
+332.85%
1-Day Range:
$1.79
$2.12
1-Week Range:
$1.59
$2.12
52-Week Range:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
2.04 | 38.05M | 1.38M | -179.05M | -155.03M | -6.14 |
|
ZTS
Zoetis Inc
|
125.67 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.90 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.05 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
52.88 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru
BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq
BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria
BioXcel plans FDA submission for at-home agitation treatment - Investing.com India
BTAI FinancialsIncome Statement - Quiver Quantitative
BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative
Drugmaker moves to bring at-home relief for bipolar agitation - Stock Titan
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN
Will BioXcel Therapeutics Inc. stock see insider buying2025 Sector Review & Real-Time Chart Breakout Alerts - moha.gov.vn
Vipin Agarwal Net Worth (2025) - GuruFocus
What MACD trends signal for BioXcel Therapeutics Inc. (BX20) stockWeekly Market Report & Community Driven Trade Alerts - Улправда
EPS Watch: How robust is BioXcel Therapeutics Inc. (BX20) stock financial position2025 Earnings Surprises & AI Powered Market Entry Strategies - Улправда
Gap Down: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Can BioXcel Therapeutics Inc. stock maintain growth trajectoryEarnings Overview Summary & Verified Swing Trading Watchlist - Улправда
Risk Off: Will BioXcel Therapeutics Inc. stock see insider buying2025 Growth vs Value & AI Driven Stock Reports - Улправда
BioXcel Therapeutics (BTAI) Stock Analysis Report | Financials & Insights - Benzinga
Loss Report: Will BioXcel Therapeutics Inc. stock see insider buyingJuly 2025 Update & Daily Volume Surge Trade Alerts - Улправда
BioXcel Therapeutics Earnings Notes - Trefis
BioXcel Therapeutics holds annual stockholders meeting - MSN
BioXcel Therapeutics Holds Annual Stockholders Meeting - TipRanks
BioXcel Therapeutics (NASDAQ: BTAI) wins approval for reverse stock split plan - Stock Titan
BTAI: All proposals, including director elections and a reverse split amendment, were approved - TradingView — Track All Markets
BioXcel Therapeutics Inc To Host Virtual Roundtable with Leading Medical Experts Transcript - GuruFocus
Aug Decliners: What MACD trends signal for BioXcel Therapeutics Inc BX20 stockJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - moha.gov.vn
Can BioXcel Therapeutics Inc. (BX20) stock sustain free cash flowQuarterly Growth Report & Weekly High Return Opportunities - Newser
What Analysts Think Is Changing The Story For BioXcel Therapeutics Now - Yahoo Finance
Can BioXcel Therapeutics Inc. stock beat analyst upgrades2025 Biggest Moves & Real-Time Sentiment Analysis - Newser
Is BioXcel Therapeutics Inc. (BX20) stock a fit for income portfoliosM&A Rumor & Fast Entry Momentum Alerts - Newser
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions - The Manila Times
Award-Winning Journalist Anjalee Khemlani to Host Virtual - GlobeNewswire
BioXcel Therapeutics (BTAI) hosts Dec. 8 virtual panel on at-home agitation treatment - Stock Titan
What is the fair value of BioXcel Therapeutics Inc. stock nowJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
Is BioXcel Therapeutics Inc. (BX20) stock worth holding before Fed meeting2025 Winners & Losers & Technical Entry and Exit Tips - Newser
Can BioXcel Therapeutics Inc. stock resist market sell offsTrade Volume Report & Technical Pattern Alert System - BỘ NỘI VỤ
FDA Approves New Indication for BioXcel Therapeutics' Igalmi (BT - GuruFocus
Why BioXcel Therapeutics Inc. (BX20) stock could be next leaderMarket Volume Summary & AI Enhanced Trading Alerts - newser.com
Can BioXcel Therapeutics Inc. stock deliver consistent earnings growthEarnings Recap Summary & Consistent Return Investment Signals - newser.com
Is BioXcel Therapeutics Inc. stock attractive after correctionQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Why BioXcel Therapeutics Inc. (BX20) stock is listed among top recommendationsEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Will BioXcel Therapeutics Inc. stock see PE expansionJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
Can BioXcel Therapeutics Inc. stock beat market expectations this quarterTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
BioXcel Therapeutics Inc. (BTAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is BioXcel Therapeutics Inc. (BX20) stock vulnerable to rate hikesChart Signals & Daily Entry Point Alerts - newser.com
What dividend safety score for BioXcel Therapeutics Inc. stockEarnings Miss & Community Verified Trade Signals - newser.com
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.03%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):